At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

Viking Therapeutics (NASDAQ:VKTX), often touted as an attractive obesity play, shed more than a third of its value this week ...

The technology sector makes up just over a third of the S&P 500 with a 34% weighting. The tech sector includes the three ...